Most Recent
A group member in a class action against Johnson & Johnson unit DePuy has filed an appeal after he lost a challenge to his compensation determination, 12 years after the case settled.
Women who were allegedly injured by defective pelvic mesh implants can apply to set aside two approved settlements against Johnson & Johnson and Boston Scientific worth $405 million.
A judge has expressed concerns after hearing that up to 20,000 group members in three pelvic mesh class actions have yet to receive payment from $405 million in settlements approved in March last year.
A group member in a class action against Johnson & Johnson unit DePuy International has lost his bid to challenge his compensation determination 12 years after the case settled, with a judge finding that the independent counsel conducting the determination was not bound by the rules of procedural fairness.
Companies and government entities paid out less to settle class actions in 2023 than in the previous two years, with no mega settlements hitting their pocketbooks.
The runner-up in a contest to administer Johnson & Johnson's $300 million settlement of two pelvic mesh class actions has lost a challenge to a decision awarding the prize to the team of Slater & Gordon, BDO and the firm of former Shine Lawyers solicitor Jan Saddler.
A judge has approved a $41.45 million settlement in a pelvic mesh class action against manufacturers Covidien and TFS but has put off deciding on the costs of the firm that ran the case, saying it is “next to useless” when law firms appoint their own costs consultants.
Shine Lawyers has lost its bid to recover $32 million in interest on a loan it took out to run two pelvic mesh class actions against Johnson & Johnson, with a judge finding it would make a “marginal settlement less than reasonable”.
A class action over pelvic mesh products supplied by device makers Covidien and TFS has reached a global resolution with the manufacturers and their insurers which brings the recovery total in settled mesh class action close to $450 million.
A class action on behalf of women injured by alleged defective pelvic mesh will not advise group members the estimated average return from the proceeds of a settlement against defunct device manufacturer TFS’ insurer because it would be "cruel".